Breaks Categories: News

ThursdaySep 10, 2026 10:20 am

NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 2 Psilocybin Trial for Major Depressive Disorder

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (“MDD”) in the first half of 2027, with dosing expected to be completed by year-end. The Health Canada-authorized trial will enroll up to 200 participants across multiple Canadian sites and evaluate the safety and efficacy of a single supervised dose of Optimi naturally derived psilocybin, manufactured at its GMP facility. The company will exclusively own the trial results and plans…

Continue Reading

ThursdaySep 10, 2026 10:10 am

NetworkNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Launches Overwatch Patrol for GPS-Denied Dismounted Operations

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) launched Overwatch Patrol, a dismounted positioning application designed to provide continuous location information to soldiers and security personnel when GPS is jammed, spoofed, degraded or unavailable. Unveiled at the International Defense Industry Exhibition (“MSPO”) in Kielce, Poland, Overwatch Patrol operates through the company’s cloud-based Overwatch Positioning Network without additional hardware and can be delivered through a native application or standard web browser. The platform enables multiple team members to share live positions without GPS and allows…

Continue Reading

ThursdaySep 10, 2026 10:00 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as…

Continue Reading

ThursdaySep 10, 2026 9:50 am

NetworkNewsBreaks – SS Innovations International, Inc. (NASDAQ: SSII) Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach

SS Innovations International (NASDAQ: SSII) provided an update on the continued expansion and utilization of its SSi Mantra surgical robotic system, reporting 14,103 cumulative procedures as of Sept. 8, 2026, up 79% from 7,885 at year-end 2025, while its installed base increased 42% to 238 systems from 168. The SSi Mantra is now installed across 12 countries, approximately 1,500 physicians have been trained on the platform and the system has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, installation of the first SSi Mantra in Sri…

Continue Reading

ThursdaySep 10, 2026 9:40 am

NetworkNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Advances Montauban Commissioning as Key Processing Equipment Arrives

This article has been disseminated on behalf of ESGold Corp. and may include paid advertising. ESGold (CSE: ESAU) (OTCQB: ESAUF) announced the arrival of additional processing equipment at its fully permitted Montauban Gold-Silver Project in Québec as installation, integration and commissioning continue across its 1,000-tonne-per-day processing facility. The equipment includes a Sepro Mineral Systems Falcon Gravity Concentrator designed to support precious-metal recovery and industrial thickeners supplied through A.M. King for solid-liquid separation and water management. With the main mill infrastructure nearly completed, ESGold is progressively assembling and commissioning the systems required to bring Montauban into operation, including its screening and…

Continue Reading

ThursdaySep 10, 2026 9:36 am

NetworkNewsBreaks – SuperQ Quantum Computing Inc. (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) Advances Super Nova(TM) Modular Hybrid Quantum Computer

This article has been disseminated on behalf of  SuperQ Quantum Computing Inc. and may include paid advertising.  SuperQ Quantum (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) is actively developing its flagship Super Nova(TM) modular hybrid quantum computer, with the quantum hardware layer being developed at the University of Waterloo Digital Quantum Matter Lab under the supervision of superconducting quantum physics expert Professor Matteo Mariantoni. Designed to integrate with enterprise IT and high-performance computing infrastructure, Super Nova(TM) combines quantum hardware with classical CPUs and GPUs to address cost, operating-system and interoperability barriers to broader quantum computing adoption. SuperQ is also expanding its Waterloo technical team through the recruitment of multiple quantum hardware scientists focused…

Continue Reading

ThursdaySep 10, 2026 9:10 am

NetworkNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) CMO Discusses ONC010, Novel PNKP Target in BioMedWire Podcast

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Chief Medical Officer Dr. Islam Mohamed joined IBN BioMedWire Podcast to discuss lead drug candidate ONC010, the company novel approach to targeting the DNA repair enzyme polynucleotide kinase phosphatase (“PNKP”) and its planned first-in-human clinical program. Mohamed highlighted ONC010 two selectivity mechanisms — synthetic lethality designed to limit drug lethality to cancer cells that have lost PTEN or SHP-1 and nanoparticle delivery intended to concentrate the drug within tumor tissue — as well as preclinical…

Continue Reading

ThursdaySep 10, 2026 9:00 am

NetworkNewsBreaks – Lahontan Gold Corp. (TSXV: LG) (OTCQB: LGCXF) Appoints Billy Choi as Chief Financial Officer

This article has been disseminated on behalf of Lahontan Gold Corp. and may include paid advertising. Lahontan Gold (TSXV: LG) (OTCQB: LGCXF) announced it has hired Billy Choi as its new chief financial officer, with Choi expected to assume full CFO responsibilities in October 2026 following a transition period. Choi most recently served as vice president of finance at Lithium Royalty Corp., where he was involved in its initial public offering, public-company reporting, financial controls and subsequent acquisition by Altius Minerals. Lahontan said the appointment strengthens its financial management team as the company advances permitting for the Santa Fe Mine…

Continue Reading

WednesdaySep 09, 2026 2:05 pm

NetworkNewsBreaks – Forward Industries, Inc. (NASDAQ: FWDI) Urges SkyAI Shareholders to Oppose Equity Plan, Withhold Votes on Director Nominees

Forward Industries (NASDAQ: FWDI) issued an open letter to SkyAI shareholders outlining concerns about the company and urging shareholders to vote against SkyAI’s 2026 Equity Incentive Plan and withhold votes on each of its five director nominees at the Sept. 18, 2026, annual meeting. Forward cited SkyAI’s rejection of its June 15 all-stock acquisition proposal valued at $1.55 per share, which represented a 20% premium to SkyAI’s prior closing price, as well as concerns regarding related-party arrangements, financial performance and shareholder value. Forward said SkyAI’s proxy disclosed $3.3 million in 2025 consulting fees to Sol Edge Limited and warrants valued…

Continue Reading

WednesdaySep 09, 2026 10:38 am

NetworkNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Appoints Andrew Elinesky CEO, Advances Trafigura Due Diligence 

This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.  LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced the appointment of Andrew Elinesky as CEO, effective immediately, and provided updates on its Beacon Gold Mill and Trafigura Canada Limited due diligence for proposed prepayment and gold doré offtake arrangements. Elinesky brings more than two decades of senior executive and financial leadership experience and most recently served as president and CEO of Sabre Gold Mines Corp., which was acquired in February 2025. He will oversee corporate strategy, capital markets, financing and investor relations, while former CEO Paul Ténière will continue as president and a director and oversee…

Continue Reading